Aadi Bioscience Inc. (AADI)
Aadi Bioscience Statistics
Share Statistics
Aadi Bioscience has 24.7M shares outstanding. The number of shares has increased by 0.52% in one year.
Shares Outstanding | 24.7M |
Shares Change (YoY) | 0.52% |
Shares Change (QoQ) | 0.27% |
Owned by Institutions (%) | 44.28% |
Shares Floating | 18.24M |
Failed to Deliver (FTD) Shares | 200 |
FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 472.65K, so 1.92% of the outstanding shares have been sold short.
Short Interest | 472.65K |
Short % of Shares Out | 1.92% |
Short % of Float | 2.32% |
Short Ratio (days to cover) | 0.55 |
Valuation Ratios
The PE ratio is -0.83 and the forward PE ratio is -2.26. Aadi Bioscience's PEG ratio is 0.23.
PE Ratio | -0.83 |
Forward PE | -2.26 |
PS Ratio | 2.23 |
Forward PS | 1.6 |
PB Ratio | 0.52 |
P/FCF Ratio | -0.85 |
PEG Ratio | 0.23 |
Enterprise Valuation
Aadi Bioscience Inc. has an Enterprise Value (EV) of -1.49M.
EV / Earnings | 0.02 |
EV / Sales | -0.06 |
EV / EBITDA | 0.02 |
EV / EBIT | 0.02 |
EV / FCF | 0.02 |
Financial Position
The company has a current ratio of 4.72, with a Debt / Equity ratio of 0.01.
Current Ratio | 4.72 |
Quick Ratio | 4.48 |
Debt / Equity | 0.01 |
Total Debt / Capitalization | 1.19 |
Cash Flow / Debt | -47.09 |
Interest Coverage | -311.4 |
Financial Efficiency
Return on equity (ROE) is -0.63% and return on capital (ROIC) is -67.57%.
Return on Equity (ROE) | -0.63% |
Return on Assets (ROA) | -0.5% |
Return on Capital (ROIC) | -67.57% |
Revenue Per Employee | $459,509.43 |
Profits Per Employee | $-1,240,849.06 |
Employee Count | 53 |
Asset Turnover | 0.18 |
Inventory Turnover | 0.44 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -5.33% in the last 52 weeks. The beta is 0.34, so Aadi Bioscience's price volatility has been higher than the market average.
Beta | 0.34 |
52-Week Price Change | -5.33% |
50-Day Moving Average | 2.91 |
200-Day Moving Average | 2.11 |
Relative Strength Index (RSI) | 32.55 |
Average Volume (20 Days) | 363.37K |
Income Statement
In the last 12 months, Aadi Bioscience had revenue of 24.35M and earned -65.77M in profits. Earnings per share was -2.44.
Revenue | 24.35M |
Gross Profit | 21.55M |
Operating Income | -71.93M |
Net Income | -65.77M |
EBITDA | -65.36M |
EBIT | -71.93M |
Earnings Per Share (EPS) | -2.44 |
Balance Sheet
The company has 62.89M in cash and 1.27M in debt, giving a net cash position of 61.62M.
Cash & Cash Equivalents | 62.89M |
Total Debt | 1.27M |
Net Cash | 61.62M |
Retained Earnings | -268.96M |
Total Assets | 85.7M |
Working Capital | 61.5M |
Cash Flow
In the last 12 months, operating cash flow was -59.66M and capital expenditures -3.97M, giving a free cash flow of -63.63M.
Operating Cash Flow | -59.66M |
Capital Expenditures | -3.97M |
Free Cash Flow | -63.63M |
FCF Per Share | -2.36 |
Margins
Gross margin is 88.47%, with operating and profit margins of -295.36% and -270.04%.
Gross Margin | 88.47% |
Operating Margin | -295.36% |
Pretax Margin | -270.04% |
Profit Margin | -270.04% |
EBITDA Margin | -268.4% |
EBIT Margin | -295.36% |
FCF Margin | -261.29% |
Dividends & Yields
AADI does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -105.63% |
FCF Yield | -111.79% |
Analyst Forecast
The average price target for AADI is $1.75, which is -24.2% lower than the current price. The consensus rating is "Hold".
Price Target | $1.75 |
Price Target Difference | -24.2% |
Analyst Consensus | Hold |
Analyst Count | 3 |
Stock Splits
The last stock split was on Aug 27, 2021. It was a backward split with a ratio of 1:15.
Last Split Date | Aug 27, 2021 |
Split Type | backward |
Split Ratio | 1:15 |
Scores
Altman Z-Score | -4.06 |
Piotroski F-Score | 3 |